


In the Claims

Please cancel claims 27-31.

Please add new claims 38 and 39.

1. (Previously Presented) A compound of the formula (I):



wherein R¹ is a 5- to 6-membered aromatic ring which has a group of the formula: R-Z¹-X-Z²- wherein R is a hydrogen atom or a substituted or unsubstituted hydrocarbon group, X is a substituted or unsubstituted alkylene chain, and Z¹ and Z² are respectively hetero-atoms, and which may have a further substituent, the group R may bind to the 5- to 6-membered aromatic ring to form a ring, Y is a substituted or unsubstituted imino group, R² and R³ are respectively a substituted or unsubstituted aliphatic hydrocarbon group or a substituted or unsubstituted alicyclic heterocyclic group; or a salt thereof.

2. (Original) A pro-drug of the compound according to claim 1 or a salt thereof.

3. (Original) The compound according to claim 1, wherein the 5- to 6-membered aromatic ring is benzene, furan or thiophene.

4. (Previously Presented) The compound according to claim 1, wherein the 5- to 6-membered aromatic ring is benzene.

5. (Previously Presented) The compound according to claim 1, wherein R is a halogenated or unhalogenated lower alkyl group.

6. (Previously Presented) The compound according to claim 1, wherein X is $-(CH_2)_n-$ wherein n is an integer of 1-4.

7. (Previously Presented) The compound according to claim 1, wherein Z^1 and Z^2 are respectively -O-, $-S(O)_m-$ wherein m is an integer of 0-2 or $-N(R^4)-$ wherein R^4 is a hydrogen atom or a substituted or unsubstituted lower alkyl group.

8. (Previously Presented) The compound according to claim 1, wherein Z^1 is -O- or $-S(O)_m-$ wherein m is an integer of 0-2.

9. (Original) The compound according to claim 1, wherein Z^1 is -O-.

10. (Previously Presented) The compound according to claim 1, wherein Z^2 is -O- or $-N(R^4)-$ wherein R^4 is a hydrogen atom or a substituted or unsubstituted lower alkyl group.

11. (Original) The compound according to claim 1, wherein Z^2 is -O-.

12. (Previously Presented) The compound according to claim 1, wherein Y is $-N(R^5)-$ wherein R^5 is a hydrogen atom, a substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted acyl group.

13. (Previously Presented) The compound according to claim 12, wherein R^5 is C_{1-4} alkyl, formyl or C_{2-5} alkanoyl.

14. (Previously Presented) The compound according to claim 12, wherein R^5 is a group represented by the formula $-(CH_2)_k-R^6$; wherein k is 0 or 1, and R^6 is a substituted or unsubstituted 5- to 6-membered monocyclic aromatic group.

15. (Previously Presented) The compound according to claim 1, wherein R^2 is a substituted or unsubstituted straight chain hydrocarbon group.

16. (Previously Presented) The compound according to claim 1, wherein R^2 is a substituted or unsubstituted lower alkyl group.

17. (Previously Presented) The compound according to claim 1, wherein R^3 is a substituted or unsubstituted alicyclic hydrocarbon group or a substituted or unsubstituted alicyclic heterocyclic group.

18. (Original) The compound according to claim 17, wherein the alicyclic hydrocarbon group is a lower cycloalkyl group.

19. (Original) The compound according to claim 17, wherein the alicyclic hydrocarbon group is cyclohexyl.

20. (Original) The compound according to claim 17, wherein the alicyclic heterocyclic group is a saturated alicyclic heterocyclic group.

21. (Original) The compound according to claim 17, wherein the alicyclic heterocyclic group is tetrahydropyranyl, tetrahydrothiopyranyl or piperidyl.

22. (Original) The compound according to claim 17, wherein the alicyclic heterocyclic group is tetrahydropyranyl.


23. (Previously Presented) A compound selected from the group consisting of 7-(4-ethoxyethoxyphenyl)-1-ethyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-ethyl-7-(4-propoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-ethyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-ethoxyethoxyphenyl)-1-formyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-formyl-7-(4-propoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-formyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-1-propyl-2,3-dihydro-1-benzazepine-4-carboxamide, N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-7-(4-propoxyethoxyphenyl)-1-propyl-2,3-dihydro-1-benzazepine-4-carboxamide, 1-benzyl-7-(4-butoxyethoxyphenyl)-N-

[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-cyclopropylmethyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-phenyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(3,4-methylenedioxy)phenyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(2-methyloxazol-5-yl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-allyl-7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(3-thienyl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(thiazol-2-yl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(1-methylpyrazol-4-yl)methyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(3-methylisothiazol-4-yl)methyl-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(1-ethylpyrazol-4-yl)methyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-7-(4-propoxyethoxyphenyl)-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(thiazol-5-yl)methyl-2,3-dihydro-1-

benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(1-methyltetrazol-5-yl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(2-methyltetrazol-5-yl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide and salts thereof.


24. (Original) A pro-drug of the compound according to claim 23 or a salt thereof.

25. (Previously Presented) A method for producing a compound of the formula I:




wherein R¹ is a 5- to 6-membered aromatic ring which has a group of the formula: R-Z¹-X-Z²- wherein R is a hydrogen atom or a substituted or unsubstituted hydrocarbon group, X is a substituted or unsubstituted alkylene chain, and Z¹ and Z² are respectively hetero-atoms, and which may have a further substituent, the group R may bind to the 5- to 6-membered aromatic ring to form a ring, Y is a substituted or unsubstituted imino group, R² and R³ are respectively a substituted or unsubstituted aliphatic hydrocarbon group or a substituted or unsubstituted alicyclic heterocyclic group; or a salt thereof,

which comprises subjecting a compound of the formula:



wherein R¹ and Y are as defined above, a salt or a reactive derivative thereof
to a condensation reaction with a compound of the formula:



wherein R² and R³ are as defined above, or a salt thereof;
and then optionally isolating said compound of formula I or a salt thereof.

26. (Previously Presented) A pharmaceutical composition which comprises the compound according to claim 1 or a salt thereof and a pharmaceutically acceptable carrier, excipient, binder or diluent.

Claims 27-31 (Cancelled)

32. (Withdrawn) The composition according to claim 29, which is used in combination with a protease inhibitor and/or a reverse transcriptase inhibitor.

33. (Withdrawn) The composition according to claim 32, wherein the reverse transcriptase inhibitor is zidovudine, didanosine, zalcitabine, lamivudine, stavudine, nevirapine, delavirdine, efavirenz or abacavir.

34. (Withdrawn) The composition according to claim 32, wherein the protease inhibitor is saquinavir, ritonavir, indinavir or nelfinavir.

35. (Previously Presented) A method for treating infectious diseases of HIV comprising administering a pharmaceutically effective amount of a compound of claim 1 or a salt thereof in combination with a protease inhibitor, a reverse transcriptase inhibitor or a combination thereof to a mammal in need thereof.

36. (Original) A method for antagonizing a CC chemokine receptor in a mammal, which comprises administering an effective amount of a compound according to claim 1 or a salt thereof to a mammal.

37. (Previously Presented) A method for treating AIDS comprising administering a pharmaceutically effective amount of a compound of claim 1 or a salt thereof to a mammal in need thereof.

38. (New) A method for antagonizing CCR5 in a mammal comprising administering an effective amount of a compound of claim 1 or a salt thereof to a mammal.
39. (New) A method for treatment of infectious disease of HIV comprising administering an effective amount of a compound of claim 1 or a salt thereof to a mammal in need thereof.